SCHEMBL2815618

SCHEMBL2815618

Cc1ccc(-c2n[nH]c3ncc4c(c23)C(=O)N(CCc2ccccc2)C4=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CNR1 P21554 1/20 0.37
CYP1B1 Q16678 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL540610 0.93 ALDH1A1 (0.44) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL13130807 0.90 MAPK14 (0.44) CASP3SMN1; SMN2LMNAMAPTALDH1A1
SCHEMBL2821038 0.89 TP53 (0.38) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2815733 0.87 ALDH1A1 (0.41) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2816145 0.87 MAP2K4 (0.39) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2815207 0.86 ALDH1A1 (0.43) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2816620 0.85 ALDH1A1 (0.38) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2818072 0.85 GRIN1 (0.39) SMN1; SMN2LMNAMAPTALDH1A1GAA
SCHEMBL2817911 0.84 ALDH1A1 (0.44) CASP3SMN1; SMN2MAPTALDH1A1GAA
SCHEMBL2818495 0.84 CYP1B1 (0.42) CASP3SMN1; SMN2LMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
US-8906928-B2 Substituted pyrazolo-pyrrolo-pyridine-dione compounds ARQULE, INC. (US) 2014-12-09 US disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249120-A1 SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS MKI67, TP53, PDK1 CASP3 1117/4885SMN1; SMN2 3380/4885LMNA 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.